MBX Biosciences: Testing 2026 May Deliver Another Year Of Share Price Gains [Seeking Alpha]
MBX Biosciences, Inc. (MBX)
Company Research
Source: Seeking Alpha
MBX's $392M cash balance and recent $200M raise provide funding into 2029, supporting multiple Phase 2/3 readouts and mitigating near-term financial risk. Imapextide and MBX-4291 offer pipeline diversification, though both are early-stage and considered hedges rather than primary value drivers. Potential M&A interest from Big Pharma and pivotal canvuparatide data could drive 50% MBX share price growth in 2026, with sub-$20 entry points attractive. sasirin pamai/iStock via Getty Images Investment Overview I have covered MBX Biosciences, Inc. ( MBX ) twice in notes for Seeking Alpha this year, the first time on May 31st , and the second time on September 22nd , both More on my IG service If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston Bi
Show less
Read more
Impact Snapshot
Event Time:
MBX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MBX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MBX alerts
High impacting MBX Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
MBX
News
- MBX Biosciences (NASDAQ:MBX) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "strong sell" rating.MarketBeat
- MBX Biosciences (MBX) Is Down 9.7% After Goldman Sell Call and MPM Exit - What's Changed [Yahoo! Finance]Yahoo! Finance
- MBX Biosciences (NASDAQ:MBX) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "sell" rating and a $18.00 price target on the stock.MarketBeat
- Take the Zacks Approach to Beat the Markets: MBX Biosciences, Garrett Motion & Monster Beverage in Focus [Yahoo! Finance]Yahoo! Finance
- How Much Upside is Left in MBX Biosciences, Inc. (MBX)? Wall Street Analysts Think 80.6% [Yahoo! Finance]Yahoo! Finance
MBX
Earnings
- 11/6/25 - Beat
MBX
Sec Filings
- 12/9/25 - Form EFFECT
- 11/25/25 - Form 4
- 11/14/25 - Form SCHEDULE
- MBX's page on the SEC website